Program
Day 4 │Friday 3 February |
|
KEYNOTE LECTURE |
|
Chair: Lauri Eklund |
|
9.00 – 9.40 |
Translational Insights into Vascular Growth Factors Kari Alitalo │University of Helsinki, Finland |
9.40 – 9.45 |
Patient story |
SESSION COMPLEX LYMPHATIC ANOMALIES & SIGNALING |
|
Chairs: Elisabeth Tournier-Lasserve and Murat Alpaslan |
|
9.45 – 10.15 |
Mechanisms of lymphatic vascular specialisation Tatiana Petrova │ University of Lausanne, Switzerland |
10.15 – 10.30 |
Pathogenic EPHB4 variants of lymphatic-related non-immune hydrops fetalis and CM-AVM2 have discernible functional effects Pascal Brouillard │ de Duve Institute, Brussels, Belgium |
10.30 – 11.00 |
Hyperactive KRAS signaling in complex lymphatic anomalies Mike Dellinger │ UT Southwestern Medical Center, Dallas, USA |
11.00 – 11.20 |
coffee break |
11.20 – 11.35 |
Mosaic activating variants in KRAS cause central conducting lymphatic anomaly which respond to MEK inhibition Sarah Sheppard │ Eunice Kennedy Shriver National Institute of Child Health and Human Development, USA |
11.35 – 11.50 |
Kaposiform Lymphangiomatosis (KLA): Update on clinical features, treatment approach, and use of targeted medical therapy Whitney Eng │ Boston Children's Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, USA |
11.50 - 12.20 |
Complicated Lymphatic Anomalies: A Developmental Therapeutic Conundrum Denise Adams │ Children’s Hospital of Philadelphia, USA |
12.20 – 13.00 |
lunch break |
KEYNOTE LECTURE |
|
Chair: Miikka Vikkula |
|
13.00 – 13.40 |
Infantile hemangioma: a paradigm for human vasculogenesis Joyce Bischoff │ Boston Children’s Hospital and Harvard Medical School, Boston, USA |
SESSION VASCULAR TUMOURS & CMS |
|
Chairs: Konstantin Gängel and Hans Schoofs |
|
13.40 – 14.10 |
Targeting transcription in vascular neoplasms Mat François │ Centenary Institute, University of Sydney, Australia |
14.10 – 14.25 |
Lymphatic endothelial precursor cells as a novel model for translational Kaposi's sarcoma studies Krista Tuohinto │University of Helsinki, Finland
|
14.25 – 14.40 |
Sirolimus to treat infantile hemangioma: report of 2 cases An Van Damme │ Cliniques universitaires Saint-Luc, Brussels, Belgium |
14.40 – 14.55 |
Statins inhibit vasculogenesis in a xenograft model of infantile hemangioma Annegret Holm │ Boston Children's Hospital, Harvard Medical School, USA |
14.55 – 15.10 |
Management of late sequellae of Kaposiform hemangioendothelioma Julien Coulie │ Cliniques universitaires Saint-Luc, Brussels, Belgium |
15.10 – 15.40 |
GNAQ mutation in the endothelium causes aberrant vascular morphogenesis and coagulopathy that are rescued by MEK inhibition Elisa Boscolo │ Cincinnati Children’s Hospital Medical Center, University of Cincinnati, USA |
15.40 – 15.55 |
Somatic PIK3R1 and non-hotspot PIK3CA mutations associated with a newly identified clinical phenotype: Capillary Malformation with Dilated Veins (CMDV) Martina de Bortoli │ VA Cure - de Duve Institute, Belgium |
15.55 – 16.00 |
Awards and closing |
|
|
|
|